Загрузка...
What have we learnt from Vioxx?
In October UK patients who had cardiovascular events while taking rofecoxib lost the right to fight Merck in the US for compensation. But researchers and journals can still benefit from this case if they learn from the mistakes, write Harlan Krumholz and colleagues
Сохранить в:
| Главные авторы: | , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BMJ Publishing Group Ltd.
2007
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC1779871/ https://ncbi.nlm.nih.gov/pubmed/17235089 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/bmj.39024.487720.68 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|